At the end of the latest market close, Supernus Pharmaceuticals Inc. (SUPN) was valued at $26.72. In that particular session, Stock kicked-off at the price of $28.50 while reaching the peak value of $30.13 and lowest value recorded on the day was $28.50. The stock current value is $30.11.
Recently in News on April 2, 2021, Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD. Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Supernus Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $31.99 on 02/10/21, with the lowest value was $23.18 for the same time period, recorded on 03/05/21.
Supernus Pharmaceuticals Inc. (SUPN) full year performance was 76.18%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Supernus Pharmaceuticals Inc. shares are logging -5.88% during the 52-week period from high price, and 81.99% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $16.55 and $31.99.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2554183 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Supernus Pharmaceuticals Inc. (SUPN) recorded performance in the market was 19.67%, having the revenues showcasing 19.67% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.56B, as it employees total of 563 workers.
Analysts verdict on Supernus Pharmaceuticals Inc. (SUPN)
During the last month, 0 analysts gave the Supernus Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 25.91, with a change in the price was noted +6.53. In a similar fashion, Supernus Pharmaceuticals Inc. posted a movement of +27.69% for the period of last 100 days, recording 619,723 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for SUPN is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.49.
Supernus Pharmaceuticals Inc. (SUPN): Technical Analysis
Raw Stochastic average of Supernus Pharmaceuticals Inc. in the period of last 50 days is set at 78.66%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 99.62%. In the last 20 days, the company’s Stochastic %K was 78.16% and its Stochastic %D was recorded 67.55%.
Let’s take a glance in the erstwhile performances of Supernus Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 19.67%. Additionally, trading for the stock in the period of the last six months notably improved by 40.31%, alongside a boost of 76.18% for the period of the last 12 months. The shares increased approximately by 14.79% in the 7-day charts and went down by 24.68% in the period of the last 30 days. Common stock shares were driven by 19.67% during last recorded quarter.